Apotheek Van den Berghe
ActiveSummary
Apotheek Van den Berghe has been active since 2009 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €341,885 and a net result of €70,216. Equity has been growing by about 13% per year since 2018. Its solvency ranks better than 57% of 12,775 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Overview
Official details
Source: KBO- Status
- Active since 23-12-2009 Normal situation
- Activity
- Retail sale of pharmaceutical products NACE 47730
- Joint committee
- 313 Paritair Comité voor de apotheken en tarificatiediensten · annual accounts 2025
- Establishment units
- 2.184.256.292 9820 Merelbeke-Melle, since 23-12-2009
- 2.315.689.809 9050 Gent, since 01-01-2020
- Financial year end
- 31 December
- Peppol
- Reachable since 06-06-2025
Board and ownership
- JOLIBARDirector · permanent representative VAN DEN BERGHE Bart
- JOLIBAR100%· score 952025 annual accounts of JOLIBAR
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.1%
- Gross margin
- €350,327
- ▼ 2.0%
- Turnover
- ≈ €1.3m
- estimated
- Profit
- €70,216
- ▲ 43.1%
- Equity
- €341,885
- ▲ 0.1%
- Total assets
- €787,581
- ▼ 6.1%
- Employees on 31-12-2025
- 4
- =
Score breakdownlowers riskLiquidity: current ratio 2.99, cash €115,070Founded in 2009Figures for financial year 2025 (filed on 22-07-2026)Equity €341,885 (43.4% of total assets)Show the evidence
Checked score
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 58% of them on solvency, 68% on liquidity, 71% on profitability and 39% on growth.
The bankruptcy probability was computed on 02-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 14 days before the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
Key points
Recent changes
- · Gazette deed Change of role: JOLIBAR, from manager to directorPermanent representative: VAN DEN BERGHE Bart
- · Gazette deed Incorporation
Comparable companies
These companies have the same main activity as Apotheek Van den Berghe: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €736,000 and €1m, founded between 2007 and 2012.
| Company | Total assets | Gross margin |
|---|---|---|
| Apotheek Van den Berghe Merelbeke-Melle | €787,581 | €350,327 |
| APOTHEEK VANLERBERGHE Diksmuide | €735,872 | €317,089 |
| APOTHEEK DU FAUX - MERELBEKE Merelbeke-Melle | €868,927 | €354,852 |
| GEASSOCIEERDE APOTHEEK DHONDT Gavere | €806,404 | €390,973 |
| APOTHEEK L. DE BOLLE Ninove | €802,923 | €334,854 |
| Apotheek Mouton Evergem | €999,574 | €397,175 |
| Apotheek De Stoop Deinze Deinze | €837,549 | €347,612 |
Key facts about Apotheek Van den Berghe
- What is the company number of Apotheek Van den Berghe?
- The company number of Apotheek Van den Berghe is 0821.730.352. The VAT number is the same number with BE in front: BE 0821.730.352.
- Where is Apotheek Van den Berghe based?
- The registered office is at Hundelgemsesteenweg 268, 9820 Merelbeke-Melle.Company details
- What does Apotheek Van den Berghe do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of Apotheek Van den Berghe?
- The legal form of Apotheek Van den Berghe is Private limited company (BV).
- When was Apotheek Van den Berghe founded?
- Apotheek Van den Berghe was founded on 23-12-2009.
- Is Apotheek Van den Berghe still active?
- Yes, Apotheek Van den Berghe is an active enterprise in the KBO register.
- How many employees does Apotheek Van den Berghe have?
- Apotheek Van den Berghe had an average of 2.8 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does Apotheek Van den Berghe fall under?
- In its 2025 annual accounts, Apotheek Van den Berghe states joint committee 313 (Paritair Comité voor de apotheken en tarificatiediensten).
- What is the turnover of Apotheek Van den Berghe?
- The turnover in financial year 2025 is ≈ €1.3m. This figure is estimated from the gross margin of €350,327 and 47 comparable companies (NACE 477). It probably lies between €990,000 and €2.1m.
- Is Apotheek Van den Berghe profitable?
- In financial year 2025, Apotheek Van den Berghe made a profit of €70,216.
- Where can I find the annual accounts of Apotheek Van den Berghe?
- Apotheek Van den Berghe filed 16 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Apotheek Van den Berghe due?
- Apotheek Van den Berghe must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.